Polymorphous cutaneous and chronic multisystem sarcoidosis.

Sarcoidosis is a systemic disorder in which cutaneous findings are often prominent. These may be polymorphous to the extent that sarcoidosis may mimic many other cutaneous diseases. We describe a 56-year-old woman with involvement of the skin, eyes, bones, heart, and lung.

Interleukin-6 and some acute phase proteins plasma activity in drug-induced maculopapular eruptions.

The evaluation of inflammatory response in drug-induced maculopapular eruption was the aim of the study. Plasma concentrations of interleukin-6 (IL-6), C-reactive protein (CRP) and alpha-2 macroglobulin (alpha-2 MG) were measured in 40 patients with maculopapular eruptions using the immunoenzymatic ELISA method in acute stage of disease and after clearing of skin lesions due to effective therapy. In the acute stage of the disease mean plasma levels of the examined proteins were highly significantly elevated (p < 0.

Activity of Tumor Necrosis Factor-alpha (TNF-alpha) and its soluble type I receptor (p55TNF-R) in some drug-induced cutaneous reactions.

Plasma concentration of TNF-alpha and its type I receptor (p55TNF-R) was examined in 126 patients with drug-induced skin reactions using immunoenzymatic ELISA method. Patients were subdivided into 6 groups: maculopapular eruptions (ME), erythema multiforme (EM), erythema multiforme coexisting with erythema nodosum (EMN), hyperergic vasculitis (HV), Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN). In the acute clinical stage highly significant (p<0.

Interleukin-2 and its soluble receptor in selected drug-induced cutaneous reactions.

Plasma concentrations of interleukin-2 (IL-2) and its soluble receptor (sIL-2R) were examined in 126 patients with drug-induced skin reactions: maculopapular eruptions (ME), erythema multiforme (EM), erythema multiforme coexisting with erythema nodosum (EMN), drug-induced urticaria (DU), hyperergic vasculitis (HV), Stevens-Johnsson syndrome and toxic epidermal necrolysis (SJS/TEN). The activity of both proteins were measured using immunoenzymatic ELISA method: a) in the acute stage of disease, before treatment was administered, and b) after clearing of skin symptoms, after treatment. In the acute stage of disease highly elevated mean concentrations of IL-2 and sIL-2R in all 6 groups of patients were found (p<0.

Plasma activity of interleukin-10 in drug-induced cutaneous reactions.

Plasma concentrations of interleukin-10 (IL-10) were examined in 126 patients with drug-induced cutaneous reactions: maculopapular eruptions (ME), erythema multiforme (EM), erythema multiforme coexisting with erythema nodosum (EMN), drug-induced urticaria (DU), hyperergic vasculitis (HV), Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN). Activity of the cytokine was measured using the immunoenzymatic ELISA method: a) in the acute stage of disease before treatment was administered, and b) after clearing of skin lesions, after treatment. In the acute stage of disease highly elevated mean concentrations of IL-10 in all 6 groups of patients were found (p<0.

Drug-induced hyperergic vasculitis--activity of selected cytokines and acute phase proteins in plasma.

Plasma concentrations of 8 proteins, including cytokines: interleukin-2 (IL-2), interleukin-6 (IL-6), interleukin-10 (IL-10), tumor necrosis factor-alpha (TNF-alpha), receptors: soluble IL-2 receptor (slL-2R), p55 soluble TNF receptor (p55 sTNF-R) and acute phase proteins: alpha-2 macroglobulin (alpha-2 MG), C-reactive protein (CRP) were examined in 14 patients with drug-induced hyperergic vasculitis. The activity of selected proteins were measured using the immunoenzymatic ELISA method: a) in the acute stage of disease before treatment was administered, and b) after clearing of skin lesions, after treatment. In the acute stage of disease highly elevated concentrations of the examined proteins (p<0.

Drug-induced urticaria--activity of selected cytokines and acute phase proteins in plasma.

Plasma concentrations of 8 proteins, including cytokines: interleukin-2 (IL-2), interleukin-6 (IL-6), interleukin-10 (IL-10), tumor necrosis factor-alpha (TNF-alpha), receptors: soluble IL-2 receptor (sIL-2R), p55 soluble TNF receptor (p55 sTNF-R) and acute phase proteins: alpha-2 macroglobulin (alpha-2 MG), C-reactive protein (CRP) were examined in 33 patients with drug-induced urticaria. The activity of selected proteins was measured using the immunoenzymatic ELISA method: a) in the acute stage of disease before treatment was administered, and b) after clearing of skin lesions, after treatment. In the acute stage of disease elevated concentrations of the examined proteins (p<0.

Collagenoses and cutaneous manifestations of hepar diseases.

The authors discuss cutaneous manifestations of some systemic diseases (collagenoses) and their connection with diseases of liver cells.

Plasma activity of interleukin-6 and some acute phase proteins in severe drug-induced skin adverse reactions.

Plasma concentrations of Interleukin-6 (IL-6), C-reactive protein (CRP) and alpha-2 macroglobulin (alpha-2 MG) were examined in 9 patients with severe drug-induced cutaneous reactions (3 patients with toxic epidermal necrolysis and 6 patients with Stevens-Johnson syndrome). The activity of selected protein was measured using the immunoenzymatic ELISA method: a) in the acute stage of disease, before the treatment was applied and b) after clearing of skin lesions due to effective treatment. In the acute stage of the disease considerably increased plasma levels of IL-6 (p < 0.

Activity of Tumor Necrosis Factor-alfa (TNF-alpha) and selected acute phase proteins in plasma of psoriatic patients receiving local treatment.

Plasma concentrations of Tumor Necrosis Factor-alpha (TNF-alpha), C-reactive protein (CRP) and alpha-2 macroglobulin (alpha-2 MG) were examined in 100 patients with medium-severe and severe psoriasis. Activity of selected proteins were measured using the ELISA method in the active stage of psoriasis and in remission achieved due to the local treatment with 0.125-2% dithranol treatment.

Plasma levels of sICAM-1 in patients affected by psoriasis: no relation to disease severity.

The aim of the study was to determine the plasma level of sICAM-1 in acute psoriatic patients in contrast to normal subjects. Moreover, we have tried to answer whether disease severity index (PASI) correlates with plasma level of sICAM-1. We have determined the plasma levels of sICAM-1 by ELISA (Genzyme Corporation) in 23 patients with acute psoriasis before and after the treatment of the disease and in 11 controls.

Incontinentia pigmenti (Bloch-Sulzberger syndrome): multisystem disease observed in two generations.

Incontinentia pigmenti is a rare genodermatosis that most commonly involves the skin, eyes, teeth, and central nervous system. We describe it in two generations. Two twin girls were observed at birth with a characteristic whorling pattern of erythema, patch, and plaques, and were later found to have dental anomalies and eye findings consisting of black pigment granules around the macula and optic nerve head.

[Treatment of crural varicose with topical dressings of "synthetic skin"].

In Dermatological Department of the Lublin Medical Academy 22 patients with crural varicose ulcerations have been treated with topical Codogard dressings. Before this treatment the patients were given some antiinflammatory and vasodilatatory drugs. The treatment lasted from 4 to 12 weeks (mean 6).